The effects of repeated administrations of MK-801 on ERK and GSK-3β signalling pathways in the rat frontal cortex

International Journal of Neuropsychopharmacology

Volumn 10, Issue 3, 2007, Pages 359-368

  Seo, Myoung Suk ^a   Kim, Se Hyun ^b   Ahn, Yong Min ^b   Kim, Yeni ^b   Jeon, Won Je ^a   Yoon, Se Chang ^c   Roh, Myoung Sun ^d   Juhnn, Yong Sung ^b   Kim, Yong Sik ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Chungyung Mental Hospital   (South Korea)

Author keywords

Akt; CREB; MAPK; NMDA receptor antagonist; Psychotomimetics

Indexed keywords

DIZOCILPINE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; FRONTAL CORTEX; LONG TERM EXPOSURE; MALE; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; RAT; REPEAT PROCEDURE; SIGNAL TRANSDUCTION;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; HSP72 HEAT-SHOCK PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; POLY(ADP-RIBOSE) POLYMERASES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 34247881864     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706006869     Document Type: Article

References (50)

1. Ahn YM, Seo MS, Kim SH, Kim Y, Juhnn YS, Kim YS (2005a). The effects of MK-801 on the phosphorylation of Ser338-c-Raf-MEK-ERK pathway in the rat frontal cortex. International Journal of Neuropsychopharmacology. doi: 10.1017/S1461145705005882. Published online: 4 August 2005.
2. Ahn YM, Seo MS, Kim SH, Kim Y, Yoon SC, Juhnn YS, Kim YS (2005b). The increased phosphorylation of Ser473-AKT, Ser9-GSK-3β and Ser133-CREB in the rat frontal cortex after MK-801 intraperitoneal injection. International Journal of Neuropsychopharmacology 8, 607-613.
3. Andine P, Axelsson R, Jacobson I (1995). The effect of anosmia on MK-801-induced behaviour in mice. Neuroscience Letters 190, 113-116.
4. Bading H, Greenberg ME (1991). Stimulation of protein tyrosine phosphorylation by NMDA receptor activation. Science 253, 912-914.
5. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, Lovestone S, Anderton B, Everall I (2001). Glycogen synthase kinase-3β immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neuroscience Letters 302, 117-120.
6. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47, 351-354.
7. Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB (2005). Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biological Psychiatry 57, 617-623.
8. Carey RJ, Dai H, Krost M, Huston JP (1995). The NMDA receptor and cocaine: evidence that mk-801 can induce behavioral sensitization effects. Pharmacology Biochemistry and Behavior 51, 901-908.
9. Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, Williams J, Sallee FR, Sharp JW, Sharp FR (2004). The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacology 47, 1135-1145.
10. Chandler LJ, Sutton G, Dorairaj NR, Norwood D (2001). N-methyl D-aspartate receptor-mediated bidirectional control of extracellular signal-regulated kinase activity in cortical neuronal cultures. Journal of Biological Chemistry 276, 2627-2636.
11. Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, Olney JW (1997). Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Research 752, 1-14.
12. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
13. Dalby KN, Morrice N, Caudwell FB, Avruch J, Cohen P (1998). Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. Journal of Biological Chemistry 273, 1496-1505.
14. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G (2003). The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. Journal of Neuroscience 23, 7311-7316.
15. Farber NB (2003). The NMDA receptor hypofunction model of psychosis. Annals of the New York Academy of Sciences 1003, 119-130.
16. Ferrer I, Planas A (2003). Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. Journal of Neuropathology and Experimental Neurology 62, 329-339.
17. Fix AS, Wozniak DF, Truex LL, McEwen M, Miller JP, Olney JW (1995). Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Research 696, 194-204.
18. Frodin M, Gammeltoft S (1999). Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Molecular and Cellular Endocrinology 151, 65-77.
19. Fumagalli F, Molteni R, Calabrese F, Frasca A, Racagni G, Riva MA (2005). Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. Journal of Neurochemistry 93, 1551-1560.
20. Gould TD, Zarate CA, Manji HK (2004). Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Journal of Clinical Psychiatry 65, 10-21.
21. Grewal SS, York RD, Stork PJ (1999). Extracellular-signal- regulated kinase signalling in neurons. Current Opinion Neurobiology 9, 544-553.
22. Grimes CA, Jope RS (2001). CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. Journal of Neurochemistry 78, 1219-1232.
23. Hetman M, Gozdz A (2004). Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. European Journal Biochemistry 271, 2050-2055.
24. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.
25. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus. Biological Psychiatry 55, 781-784.
26. Kang UG, Seo MS, Roh MS, Kim Y, Yoon SC, Kim YS (2004). The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Letters 560, 115-119.
27. Kozlovsky N, Belmaker RH, Agam G (2001). Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophrenia Research 52, 101-105.
28. Kyosseva SV (2004). Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 28, 997-1006.
29. Kyosseva SV, Owens SM, Elbein AD, Karson CN (2001). Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain. Neuropsychopharmacology 24, 267-277.
30. Li X, Friedman AB, Roh MS, Jope RS (2005). Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. Journal of Neurochemistry 92, 701-704.
31. Lu XH, Bradley RJ, Dwyer DS (2004). Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Research 1011, 58-68.
32. Molinuevo JL, Llado A, Rami L (2005). Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. American Journal of Alzheimer's Disease and Other Dementias 20, 77-85.
33. Olney JW, Farber N (1995). NMDA antagonist as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13, 335-345.
34. Papp M, Moryl E (1994). Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. European Journal of Pharmacology 22, 1-7.
35. Paxinos G, Watson C (1998). The Rat Brain in Stereotactic Coordinates (4th edn). Sydney: Academic Press.
36. Roh MS, Eom TY, Zmijewska AA, De Sarno P, Roth KA, Jope RS (2005). Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biological Psychiatry 57, 278-286.
37. Roh MS, Kang UG, Shin SY, Lee YH, Jung HY, Juhnn YS, Kim YS (2003). Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3β after electroconvulsive shock in the rat brain. Progress in Neuro-psychopharmacology and Biological Psychiatry 27, 1-5.
38. Sharp FR, Jasper P, Hall J, Noble L, Sagar SM (1991). MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Annals of Neurology 30, 801-809.
39. Sutton G, Chandler LJ (2002). Activity-dependent NMDA receptor-mediated activation of protein kinase B/Akt in cortical neuronal cultures. Journal of Neurochemistry 82, 1097-1105.
40. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P (2003). Diverse psychotomimetics act through a common signaling pathway. Science 302, 1412-1415.
41. Thomas DM, Kuhn DM (2005). MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Research 1050, 190-198.
42. Tomitaka M, Tomitaka S, Rajdev S, Sharp FR (2000). Fluoxetine prevents PCP- and MK-801-induced HSP70 expression in injured limbic cortical neurons of rats. Biological Psychiatry 47, 836-841.
43. Walton MR, Dragunow I (2000). Is CREB a key to neuronal survival? Trends Neuroscience 23, 48-53.
44. Wedzony K, Golembiowska K, Klimek V (1993). MK-801-induced symptoms of sensitization. The lack of correlation with the extracellular concentration of dopamine in the rat prefrontal cortex. Brain Research 625, 333-336.
45. Xing J, Ginty DD, Greenberg ME (1996). Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273, 959-963.
46. Yang PB, Swann AC, Dafny N (2002). Valproate prevents the induction and the expression of MK-801 sensitization. Brain Research 954, 151-159.
47. Yu B, Wang C, Liu J, Johnson KM, Gallagher JP (2002) Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors. Neuroscience 113, 1-10.
48. Zhu D, Wu X, Strauss KI, Lipsky RH, Qureshi Z, Terhakopian A, Novelli A, Banaudha K, Marini AM (2005). N-methyl-D-aspartate and TrkB receptors protect neurons against glutamate excitotoxicity through an extracellular signal-regulated kinase pathway. Journal of Neuroscience Research 80, 104-103.
49. Zarate Jr. CA, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, Charney DS, Manji HK (2003). Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Annals of the New York Academy of Sciences 1003, 273-291.
50. Zimmermann S, Moelling K (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 1741-1744.